Skip to main content
. 2015 Oct 19;6(39):41736–41749. doi: 10.18632/oncotarget.6153

Figure 3. Inhibition of PRAS40 phosphorylation by GSK2141795 in SKOV3 monolayers, spheroids and xenografts.

Figure 3

Protein concentration of phospho-PRAS40 (Thr246) and total PRAS40 was determined by enzyme-linked immunosorbent assay (ELISA) after 72hr treatment of SKOV3 cells with a range of concentrations of GSK2141795 (0.01 - 5 μM) in both monolayers and spheroids A.. GSK2141795 (30 mg/Kg) abolished phosphorylation of PRAS40 at Thr246, both as single agent and in combination with cisplatin (cddp), in SKOV3 tumour xenografts following 14 days of treatment B.. Data are presented as a phospho-PRAS40 / total PRAS40 decrease relative to untreated or vehicle treated samples. Data shown in A. are the means ± SEM of n = 2 experiments performed in triplicate, and in B. the mean ± SEM for n = 5 animals (tumours) / treatment. *p < 0.05 and **p < 0.01, where the symbols * and # represent significant differences when compared to vehicle and cisplatin data, respectively (unpaired t-test, two tailed).